Department of Pharmacology and Experimental Therapeutics

Jeannie Padowski, Ph.D.

  Clinical Associate Professor

  Department of Pharmacology and Experimental Therapeutics
  Frederic and Mary Wolfe Center 282E
  Phone: 419.383.1598
  E-mail: jeannie.padowski@utoledo.edu

 

 

Area of Research

Dr. Padowski's main research area is pharmacokinetic and pharmacodynamic modeling of CNS drug disposition, using noncompartmental and compartmental modeling and simulation to study neurodegenerative disease progression and treatment approaches, including nasal drug delivery.

In line with her experience developing active- and collaborative-learning approaches in medical and pharmacy curricula, Dr. Padowski's emerging interests are in the scholarship of teaching and learning, particularly related to pharmacology, toxicology, and pharmacokinetics. Dr. Padowski's involvement in university-level aspects of research administration and experience as an IRB chair support and align with her interest in survey-based educational research projects.

Educational Background

Ph.D. in Toxicology	University of North Carolina at Chapel Hill
B.A. in Brain & Cognitive Sciences & Psychology	University of Rochester

Training

• Postdoctoral training in Brain Imaging & Spectroscopy, University of Washington
• Postdoctoral training in Pharmacokinetics & Pharmacodynamics, University of North Carolina at Chapel Hill

Publications and Journals

1. Zhong, Y., Padowski, J., Pollack, G., Remsberg, C. Best practices for creating and utilizing pharmacokinetics course materials in an active- and collaborative-learning classroom. American Association of Colleges of Pharmacy Annual Meeting, July 2018.
2. Gufford, BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF. Comparison of a new intranasal naloxone formulation to intramuscular naloxone: results from hypothesis-generating small clinical studies. Clin Transl Sci. 2017 May 15. PMID 2850448
3. Mischley, LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb study of intranasal glutathione in Parkinson’s disease. J Parkinsons Dis. 2017;7(2):289-299. PMID 28436395.
4. Robinson, J.D., Remsberg, C.M., Bray, B.S., Brand-Eubanks, D., Buchman, C., Willson, M.N., Akers, J., Padowski, J., Daoud, S.S., Clark, J.A., Paine, M.F., Gates, B.J., Muller, S.J., MacLean, L.G., Pollack, G.M. A transformative shift: competency-based active learning at Washington State University. American Association of Colleges of Pharmacy Annual Meeting, July 2016.
5. Mischley, L.K., Standish, L.J., Weiss, N.S., Padowski, J.M., Kavanagh, T.J., White, C.C., Rosenfeld, M.E. Glutathione as a biomarker in Parkinson’s disease: associations with aging and disease severity. Oxid Med Cell Longev. 2016; 2016:9409363. Epub 2016 July. PMID: 27446510.
6. White, JR, Padowski, JM, Zhong, Y, Chen, G, Lazarus, P, Layton, ME, McPherson, S. Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot vs. chilled energy drink in healthy young adults. Clin Toxicol (Phila). 2016 Apr;54(4):308-12. PMID: 27100333.
7. Mischley, LM, Shankland, EG, Conley, KE, Kavanagh, T, Rosenfeld, M, Duda, J, White, C, Wilbur, T, DeLaTorre, P, and Padowski, JM. Central nervous system uptake of intranasal glutathione in Parkinson’s disease. NPJ Parkinson’s Disease. 2016 Feb; 2:1-6.